ArticleThe Journal of experimental medicine2018
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04792437 (Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data), which is not on this map. Cited by 160 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data
Who cites it
160 citing papers in PubMed, 1 synthesis or guideline pooled it, 212 citations in OpenAlex.
- Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.Annals of oncology : official journal of the European Society for Medical Oncology · 2020Pooled it
- Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.The Journal of clinical investigation · 2020Trial
- Immunotherapy for Diffuse Midline Glioma: From Preclinical Modeling to Clinical Translation.Cancers · 2026Review
- Sequence-Anchored Shared Tumor-Specific Epitopes for Pre-Manufactured HLA-Matched mRNA Cancer Vaccine Libraries: A Pan-Cancer Framework.Biomolecules · 2026Article
- Experimental models in immuno-oncology and their translational impact.Discover oncology · 2026Review
- Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors.Molecular diagnosis & therapy · 2026Review
- A new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma.Neuro-oncology advances · 2026Review
- Imaging assessment of immunotherapy in pediatric brain tumors.Journal of neuro-oncology · 2026Review
- Vaccine therapy for pediatric high-grade glioma: current landscape, challenges, and future directions.Journal of neuro-oncology · 2026Review
- Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026Review
- Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron-glioma interactions, and tumor microenvironment modulation.Journal of neuro-oncology · 2025Review
- Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis.Human vaccines & immunotherapeutics · 2025Article
- Article
- Targeting neoantigens conserved across organs and species overcomes tumor immune escape.bioRxiv : the preprint server for biology · 2025Article
- SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms.Cancer immunology research · 2025Article
- Recent developments in peptide vaccines against Glioblastoma, a review and update.Molecular brain · 2025Review
- Transcript-targeted antigen mapping reveals the potential of POSTN splicing junction epitopes in glioblastoma immunotherapy.Genes and immunity · 2025Article
- Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).International journal of oncology · 2025Review
- CAR T cell therapy for central nervous system solid tumors: current progress and future directions.Frontiers in immunology · 2025Review
- Vaccine therapies for glioma: clinical frontiers and potential breakthrough.Frontiers in oncology · 2025Review
100 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 8 institutions in 2 countries.
Zinal S ChhedaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Gary KohanbashDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-3953-8022
Kaori OkadaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Naznin JahanDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-7310-3890
John SidneyCenter for Infectious Disease, Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Matteo PecoraroDepartment of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Xinbo YangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA.
Diego A CarreraDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-4799-9056
Kira M DowneyDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Shruti ShrivastavDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0003-2587-2617
Shuming LiuDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Yi LinDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0001-5780-3830
Chetana LagisettiDepartment of Public Health, University of California, Berkeley, Berkeley, CA.
Pavlina ChuntovaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Payal B WatchmakerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Sabine MuellerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Ian F PollackDepartment of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.ORCID 0000-0003-1765-357X
Raja RajalingamDepartment of Surgery, Immunogenetics and Transplantation Laboratory, University of California, San Francisco, San Francisco, CA.ORCID 0000-0001-8821-7877
Angel M CarcabosoInstitut de Recerca Sant Joan de Deu, Barcelona, Spain.ORCID 0000-0002-8485-426X
Matthias MannDepartment of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Alessandro SetteCenter for Infectious Disease, Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA.
K Christopher GarciaDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA.
Yafei HouDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Hideho OkadaDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA hideho.okada@ucsf.edu.ORCID 0000-0003-0076-9920
University of California, San Francisco · USLa Jolla Institute for Immunology · USMax Planck Institute of Biochemistry · DEUniversity of Pittsburgh · USBerkeley Public Health Division · USHoward Hughes Medical Institute · USInstitut de Recerca Sant Joan de DéuStanford University · US
Funding
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6MPreclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0MNovel Immunotherapy of Glioma using miR-17-92 Transfected T CellsR01NS055140 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI OKADA, HIDEHO · 2007 to 2015
$2.6MNovel K27M Mutation-derived Neoantigen for T Cell Therapy in GliomasR01NS096954 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2016 to 2017
$693kNCI NIH HHS T32 CA151022NINDS NIH HHS R01 NS055140NINDS NIH HHS R01 NS096954NINDS NIH HHS R35 NS105068
Abstract
The median overall survival for children with diffuse intrinsic pontine glioma (DIPG) is less than one year. The majority of diffuse midline gliomas, including more than 70% of DIPGs, harbor an amino acid substitution from lysine (K) to methionine (M) at position 27 of histone 3 variant 3 (H3.3). From a CD8
Indexed as
MutationAdoptive TransferAmino AcidsAmino Acid SequenceAnimalsAntigen PresentationAntigens, NeoplasmChromatography, LiquidDisease Models, AnimalEpitope MappingFemaleGliomaHistonesHLA-A AntigensHumansImmunotherapy, AdoptiveAmino AcidsAntigens, NeoplasmHistonesHLA-A AntigensPeptidesReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
NCT04792437ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.